Van ECK Associates Corp Sells 3,539 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,399 shares of the biopharmaceutical company's stock after selling 3,539 shares during the period. Van ECK Associates Corp's holdings in Alnylam Pharmaceuticals were worth $16,925,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $30,000. Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $51,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 95.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 103 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research report on Monday, August 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a research report on Friday, August 2nd. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $294.50.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $7.72 during midday trading on Wednesday, hitting $273.01. 1,376,755 shares of the company's stock traded hands, compared to its average volume of 873,266. The firm has a fifty day moving average of $274.33 and a 200 day moving average of $228.73. The stock has a market capitalization of $35.21 billion, a price-to-earnings ratio of -101.26 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company's revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.